HIV Reverse Transcriptase
"HIV Reverse Transcriptase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A reverse transcriptase encoded by the POL GENE of HIV. It is a heterodimer of 66 kDa and 51 kDa subunits that are derived from a common precursor protein. The heterodimer also includes an RNAse H activity (RIBONUCLEASE H, HUMAN IMMUNODEFICIENCY VIRUS) that plays an essential role the viral replication process.
| Descriptor ID |
D054303
|
| MeSH Number(s) |
D08.811.913.696.445.308.300.750.187 D12.776.964.775.375.545.875 D12.776.964.775.375.750.187 D12.776.964.775.562.764.875 D12.776.964.970.600.850.375.545.875 D12.776.964.970.600.850.375.750.187
|
| Concept/Terms |
HIV Reverse Transcriptase- HIV Reverse Transcriptase
- Transcriptase, HIV Reverse
- Reverse Transcriptase, Human Immunodeficiency Virus
- Reverse Transcriptase, HIV
|
Below are MeSH descriptors whose meaning is more general than "HIV Reverse Transcriptase".
Below are MeSH descriptors whose meaning is more specific than "HIV Reverse Transcriptase".
This graph shows the total number of publications written about "HIV Reverse Transcriptase" by people in this website by year, and whether "HIV Reverse Transcriptase" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 2 | 2 |
| 1997 | 0 | 2 | 2 |
| 2005 | 0 | 2 | 2 |
| 2006 | 0 | 1 | 1 |
| 2009 | 1 | 0 | 1 |
| 2016 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "HIV Reverse Transcriptase" by people in Profiles.
-
Leporati A, Novikov MS, Valuev-Elliston VT, Korolev SP, Khandazhinskaya AL, Kochetkov SN, Gupta S, Goding J, Bolotin E, Gottikh MB, Bogdanov AA. Hydrophobic-core PEGylated graft copolymer-stabilized nanoparticles composed of insoluble non-nucleoside reverse transcriptase inhibitors exhibit strong anti-HIV activity. Nanomedicine. 2016 11; 12(8):2405-2413.
-
van Rooijen LB, Greengrass V, Morris LM, Plate MM, Gouillou M, Tachedjian G, Sluis-Cremer N, Hearps AC, Crowe SM. Effect of reverse transcriptase inhibitors and mutations on the low-cost Cavidi reverse transcriptase viral load assay. J Acquir Immune Defic Syndr. 2009 Dec 01; 52(4):527-9.
-
Wright AD, de Nys R, Angerhofer CK, Pezzuto JM, Gurrath M. Biological activities and 3D QSAR studies of a series of Delisea pulchra (cf. fimbriata) derived natural products. J Nat Prod. 2006 Aug; 69(8):1180-7.
-
Gurer C, H?glund A, H?glund S, Luban J. ATPgammaS disrupts human immunodeficiency virus type 1 virion core integrity. J Virol. 2005 May; 79(9):5557-67.
-
Balakrishnan P, Kumarasamy N, Kantor R, Solomon S, Vidya S, Mayer KH, Newstein M, Thyagarajan SP, Katzenstein D, Ramratnam B. HIV type 1 genotypic variation in an antiretroviral treatment-naive population in southern India. AIDS Res Hum Retroviruses. 2005 Apr; 21(4):301-5.
-
Soderberg K, Denekamp L, Nikiforow S, Sautter K, Desrosiers RC, Alexander L. A nucleotide substitution in the tRNA(Lys) primer binding site dramatically increases replication of recombinant simian immunodeficiency virus containing a human immunodeficiency virus type 1 reverse transcriptase. J Virol. 2002 Jun; 76(11):5803-6.
-
Desrosiers RC. Strategies used by human immunodeficiency virus that allow persistent viral replication. Nat Med. 1999 Jul; 5(7):723-5.
-
Harrison TS, Nong S, Levitz SM. Induction of human immunodeficiency virus type 1 expression in monocytic cells by Cryptococcus neoformans and Candida albicans. J Infect Dis. 1997 Aug; 176(2):485-91.
-
Cruikshank WW, Doctrow SR, Falvo MS, Huffman K, Maciaszek J, Viglianti G, Raina J, Kornfeld H, Malfroy B. A lipidated anti-Tat antibody enters living cells and blocks HIV-1 viral replication. J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Mar 01; 14(3):193-203.
-
Franke EK, Luban J. Inhibition of HIV-1 replication by cyclosporine A or related compounds correlates with the ability to disrupt the Gag-cyclophilin A interaction. Virology. 1996 Aug 01; 222(1):279-82.